Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Restricted access

Infectious diseases are important causes of morbidity and mortality in patients with cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This portion of the guidelines highlights the sections on antifungal and antiviral prophylaxis. Antifungal and antiviral prophylaxis recommendations have expanded over the past few years. New agents for the treatment of fungal infections and incorporation of therapeutic drug monitoring are presented. Antiviral prophylaxis for hepatitis B and management considerations for hepatitis C and HIV have been further developed.

  • 1.

    Aquino VM, Herrera L, Sandler ES, Buchanan GR. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 2000;88:17101714.

    • Search Google Scholar
    • Export Citation
  • 2.

    Freifeld AG, Walsh T, Marshall D. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165176.

    • Search Google Scholar
    • Export Citation
  • 3.

    Hidalgo M, Hornedo J, Lumbreras C. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999;85:213219.

    • Search Google Scholar
    • Export Citation
  • 4.

    Hughes WT, Armstrong D, Bodey GP. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730751.

    • Search Google Scholar
    • Export Citation
  • 5.

    Kern WV, Cometta A, De Bock R. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999;341:312318.

    • Search Google Scholar
    • Export Citation
  • 6.

    Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:10921096.

    • Search Google Scholar
    • Export Citation
  • 7.

    Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:13231332.

  • 8.

    Rolston KV, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin North Am 1996;10:223237.

    • Search Google Scholar
    • Export Citation
  • 9.

    Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80:1320.

  • 10.

    Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:25612568.

    • Search Google Scholar
    • Export Citation
  • 11.

    Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316322.

    • Search Google Scholar
    • Export Citation
  • 12.

    Talcott JA, Whalen A, Clark J. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107114.

    • Search Google Scholar
    • Export Citation
  • 13.

    Mihu CN, Schaub J, Kesh S. Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation: a single-institution, nested case-controlled study. Biol Blood Marrow Transplant 2008;14:14291433.

    • Search Google Scholar
    • Export Citation
  • 14.

    Neofytos D, Horn D, Anaissie E. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) alliance registry. Clin Infect Dis 2009;48:265273.

    • Search Google Scholar
    • Export Citation
  • 15.

    Rizzo JD, Wingard JR, Tichelli A. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006;12:138151.

    • Search Google Scholar
    • Export Citation
  • 16.

    Sullivan KM, Dykewicz CA, Longworth DL. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation practice guidelines and beyond. Hematology Am Soc Hematol Educ Program 2001:392421.

    • Search Google Scholar
    • Export Citation
  • 17.

    Freifeld AG, Bow EJ, Sepkowitz KA. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e5693.

    • Search Google Scholar
    • Export Citation
  • 18.

    Rotstein C, Bow EJ, Laverdiere M. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999;28:331340.

    • Search Google Scholar
    • Export Citation
  • 19.

    Goodman JL, Winston DJ, Greenfield RA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845851.

    • Search Google Scholar
    • Export Citation
  • 20.

    Slavin MA, Osborne B, Adams R. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 1995;171:15451552.

    • Search Google Scholar
    • Export Citation
  • 21.

    Marr KA, Seidel K, Slavin MA. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:20552061.

    • Search Google Scholar
    • Export Citation
  • 22.

    Kern W, Behre G, Rudolf T. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998;83:291301.

    • Search Google Scholar
    • Export Citation
  • 23.

    Winston DJ, Chandrasekar PH, Lazarus HM. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495503.

    • Search Google Scholar
    • Export Citation
  • 24.

    Wingard JR, Carter SL, Walsh TJ. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116:51115118.

    • Search Google Scholar
    • Export Citation
  • 25.

    Vazquez JA, Skiest DJ, Nieto L. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:11791186.

    • Search Google Scholar
    • Export Citation
  • 26.

    Cornely OA, Maertens J, Winston DJ. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348359.

    • Search Google Scholar
    • Export Citation
  • 27.

    Ullmann AJ, Lipton JH, Vesole DH. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335347.

    • Search Google Scholar
    • Export Citation
  • 28.

    Astellas Pharma. Prescribing information. Cresemba (isavuconazonium sulfate) capsules and intravenous use. 2015. Available at: http://www.astellas.us/docs/cresemba.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 29.

    Maertens JA, Raad II, Marr KA. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016;387:760769.

    • Search Google Scholar
    • Export Citation
  • 30.

    Marr KA, Crippa F, Leisenring W. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:15271533.

    • Search Google Scholar
    • Export Citation
  • 31.

    Marr KA, Leisenring W, Crippa F. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:15571559.

  • 32.

    US Food and Drug Administration. Isavuconazonium – invasive aspergillosis and invasive mucormycosis. Advisory Committee briefing document. 2015. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm430748.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 33.

    Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:13631372.

  • 34.

    U.S. Food and Drug Administration. Prescribing information. Sporanox (itraconazole) capsules. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020083s053lbl.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 35.

    Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999;43:21162120.

    • Search Google Scholar
    • Export Citation
  • 36.

    Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990;12(Suppl 3):S318326.

    • Search Google Scholar
    • Export Citation
  • 37.

    Clancy CJ, Yu VL, Morris AJ. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005;49:31713177.

    • Search Google Scholar
    • Export Citation
  • 38.

    Csajka C, Decosterd LA, Buclin T. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur J Clin Pharmacol 2001;57:723727.

    • Search Google Scholar
    • Export Citation
  • 39.

    Rex JH, Pfaller MA, Galgiani JN. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235247.

    • Search Google Scholar
    • Export Citation
  • 40.

    US Food and Drug Administration. Prescribing information. Diflucan (fluconazole) tablets, oral suspension, and intravenous use. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 41.

    Krishna G, Moton A, Ma L. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958966.

    • Search Google Scholar
    • Export Citation
  • 42.

    US Food and Drug Administration. Prescribing information. Noxafil (posaconazole) oral suspension, delayed-release tablet, intravenous use. 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 43.

    Gross BN, Ihorst G, Jung M. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy 2013;33:11171125.

    • Search Google Scholar
    • Export Citation
  • 44.

    Bryant AM, Slain D, Cumpston A, Craig M. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 2011;37:266269.

    • Search Google Scholar
    • Export Citation
  • 45.

    Bruggemann RJ, Touw DJ, Aarnoutse RE. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 2009;53:303305.

    • Search Google Scholar
    • Export Citation
  • 46.

    Kraft WK, Chang PS, van Iersel ML. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother 2014;58:40204025.

    • Search Google Scholar
    • Export Citation
  • 47.

    Heinz WJ, Egerer G, Lellek H. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses 2013;56:304310.

    • Search Google Scholar
    • Export Citation
  • 48.

    Maertens J, Cornely OA, Ullmann AJ. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother 2014;58:36103617.

    • Search Google Scholar
    • Export Citation
  • 49.

    Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010;88:115119.

    • Search Google Scholar
    • Export Citation
  • 50.

    Tonini J, Thiebaut A, Jourdil JF. Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease. Antimicrob Agents Chemother 2012;56:52475252.

    • Search Google Scholar
    • Export Citation
  • 51.

    Shields RK, Clancy CJ, Vadnerkar A. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother 2011;55:13081311.

    • Search Google Scholar
    • Export Citation
  • 52.

    Eiden C, Meniane JC, Peyriere H. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Microbiol Infect Dis 2012;31:161167.

    • Search Google Scholar
    • Export Citation
  • 53.

    Hoenigl M, Raggam RB, Salzer HJ. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents 2012;39:510513.

    • Search Google Scholar
    • Export Citation
  • 54.

    Lebeaux D, Lanternier F, Elie C. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009;53:52245229.

    • Search Google Scholar
    • Export Citation
  • 55.

    Howard SJ, Cerar D, Anderson MJ. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009;15:10681076.

    • Search Google Scholar
    • Export Citation
  • 56.

    Mavridou E, Bruggemann RJ, Melchers WJ. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010;54:860865.

    • Search Google Scholar
    • Export Citation
  • 57.

    Boogaerts MA, Verhoef GE, Zachee P. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32(Suppl 1):103108.

    • Search Google Scholar
    • Export Citation
  • 58.

    Tricot G, Joosten E, Boogaerts MA. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987;9(Suppl 1):S9499.

    • Search Google Scholar
    • Export Citation
  • 59.

    Glasmacher A, Hahn C, Leutner C. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999;42:443451.

    • Search Google Scholar
    • Export Citation
  • 60.

    Glasmacher A, Hahn C, Molitor E. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999;42:591600.

    • Search Google Scholar
    • Export Citation
  • 61.

    Denning DW, Tucker RM, Hanson LH. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989;149:23012308.

  • 62.

    Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791800.

  • 63.

    Sharkey PK, Rinaldi MG, Dunn JF. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35:707713.

  • 64.

    Wheat J, Hafner R, Korzun AH. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995;98:336342.

    • Search Google Scholar
    • Export Citation
  • 65.

    Lestner JM, Roberts SA, Moore CB. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009;49:928930.

    • Search Google Scholar
    • Export Citation
  • 66.

    Barone JA, Moskovitz BL, Guarnieri J. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998;18:295301.

    • Search Google Scholar
    • Export Citation
  • 67.

    Pascual A, Calandra T, Bolay S. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201211.

    • Search Google Scholar
    • Export Citation
  • 68.

    Jeans AR, Howard SJ, Al-Nakeeb Z. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2012;56:51805185.

    • Search Google Scholar
    • Export Citation
  • 69.

    Smith J, Safdar N, Knasinski V. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:15701572.

  • 70.

    Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011;55:47824788.

    • Search Google Scholar
    • Export Citation
  • 71.

    Dolton MJ, Ray JE, Chen SC. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012;56:47934799.

    • Search Google Scholar
    • Export Citation
  • 72.

    Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010;16:927933.

    • Search Google Scholar
    • Export Citation
  • 73.

    Gomez-Lopez A, Cendejas-Bueno E, Cuesta I. Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients. Med Mycol 2012;50:439445.

    • Search Google Scholar
    • Export Citation
  • 74.

    Ueda K, Nannya Y, Kumano K. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009;89:592599.

    • Search Google Scholar
    • Export Citation
  • 75.

    Trifilio S, Singhal S, Williams S. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451456.

    • Search Google Scholar
    • Export Citation
  • 76.

    Mitsani D, Nguyen MH, Shields RK. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012;56:23712377.

    • Search Google Scholar
    • Export Citation
  • 77.

    Pascual A, Csajka C, Buclin T. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012;55:381390.

    • Search Google Scholar
    • Export Citation
  • 78.

    Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis 2008;47:e7e10.

  • 79.

    Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother 2012;18:501507.

    • Search Google Scholar
    • Export Citation
  • 80.

    Kim KH, Lee S, Lee S. Voriconazole-associated severe hyponatremia. Med Mycol 2012;50:103105.

  • 81.

    Matsumoto K, Ikawa K, Abematsu K. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009;34:9194.

    • Search Google Scholar
    • Export Citation
  • 82.

    Purkins L, Wood N, Kleinermans D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003;56 Suppl 1:1723.

    • Search Google Scholar
    • Export Citation
  • 83.

    Pfizer, Inc. Prescribing information. Vfend (voriconazole) tablets, oral suspension, and intravenous use. 2015. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=618. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 84.

    Ashbee HR, Barnes RA, Johnson EM. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014;69:11621176.

    • Search Google Scholar
    • Export Citation
  • 85.

    Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53:2434.

    • Search Google Scholar
    • Export Citation
  • 86.

    Koh LP, Kurup A, Goh YT. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002;71:260267.

    • Search Google Scholar
    • Export Citation
  • 87.

    Winston DJ, Maziarz RT, Chandrasekar PH. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705713.

    • Search Google Scholar
    • Export Citation
  • 88.

    Bates DW, Su L, Yu DT. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001;60:14521459.

  • 89.

    Wingard JR, Kubilis P, Lee L. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:14021407.

    • Search Google Scholar
    • Export Citation
  • 90.

    Rijnders BJ, Cornelissen JJ, Slobbe L. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:14011408.

    • Search Google Scholar
    • Export Citation
  • 91.

    Perfect JR. Aerosolized antifungal prophylaxis: the winds of change? Clin Infect Dis 2008;46:14091411.

  • 92.

    Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003;20:121136.

    • Search Google Scholar
    • Export Citation
  • 93.

    Villanueva A, Arathoon EG, Gotuzzo E. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:15291535.

    • Search Google Scholar
    • Export Citation
  • 94.

    Maertens J, Raad I, Petrikkos G. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:15631571.

    • Search Google Scholar
    • Export Citation
  • 95.

    Kartsonis NA, Saah AJ, Joy Lipka C. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005;50:196205.

    • Search Google Scholar
    • Export Citation
  • 96.

    U.S Food and Drug Administration. Prescribing information. Mycamine (micafungin sodium) for injection; IV infusion only. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021506s015lbl.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 97.

    van Burik JA, Ratanatharathorn V, Stepan DE. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:14071416.

    • Search Google Scholar
    • Export Citation
  • 98.

    Yokote T, Akioka T, Oka S. Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy. Ann Hematol 2004;83:6466.

    • Search Google Scholar
    • Export Citation
  • 99.

    Ota S, Tanaka J, Kahata K. Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study. Int J Hematol 2004;79:390393.

    • Search Google Scholar
    • Export Citation
  • 100.

    Singer MS, Seibel NL, Vezina G. Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia. J Pediatr Hematol Oncol 2003;25:252256.

    • Search Google Scholar
    • Export Citation
  • 101.

    Krause DS, Simjee AE, van Rensburg C. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39:770775.

    • Search Google Scholar
    • Export Citation
  • 102.

    Vazquez JA, Schranz JA, Clark K. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008;48:304309.

    • Search Google Scholar
    • Export Citation
  • 103.

    Reboli AC, Rotstein C, Pappas PG. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:24722482.

  • 104.

    Bodey GP, Mardani M, Hanna HA. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002;112:380385.

    • Search Google Scholar
    • Export Citation
  • 105.

    Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309316.

    • Search Google Scholar
    • Export Citation
  • 106.

    Weinberger M, Elattar I, Marshall D. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992;71:2443.

    • Search Google Scholar
    • Export Citation
  • 107.

    Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995;76:23572362.

    • Search Google Scholar
    • Export Citation
  • 108.

    Offner F, Cordonnier C, Ljungman P. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998;26:10981103.

    • Search Google Scholar
    • Export Citation
  • 109.

    Fukuda T, Boeckh M, Guthrie KA. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004;10:494503.

    • Search Google Scholar
    • Export Citation
  • 110.

    Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980;142:338346.

    • Search Google Scholar
    • Export Citation
  • 111.

    Saral R, Burns WH, Laskin OL. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981;305:6367.

  • 112.

    Saral R, Ambinder RF, Burns WH. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 1983;99:773776.

    • Search Google Scholar
    • Export Citation
  • 113.

    Mackall C, Fry T, Gress R. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant 2009;44:457462.

    • Search Google Scholar
    • Export Citation
  • 114.

    Tomblyn M, Chiller T, Einsele H. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:11431238.

    • Search Google Scholar
    • Export Citation
  • 115.

    Zaia J, Baden L, Boeckh MJ. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:471482.

  • 116.

    Genzyme Corporation. Prescribing information. Campath (alemtuzumab) injection for intravenous use. Cambridge, MA: Genzyme Corporation; 2009. Available at: http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 117.

    Keating M, Coutre S, Rai K. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004;4:220227.

    • Search Google Scholar
    • Export Citation
  • 118.

    Boeckh M, Kim HW, Flowers MED. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood 2006;107:18001805.

    • Search Google Scholar
    • Export Citation
  • 119.

    Erard V, Guthrie KA, Varley C. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007;110:30713077.

    • Search Google Scholar
    • Export Citation
  • 120.

    Asano-Mori Y, Kanda Y, Oshima K. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008;83:472476.

    • Search Google Scholar
    • Export Citation
  • 121.

    Oshima K, Takahashi T, Mori T. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis 2010;12:421427.

    • Search Google Scholar
    • Export Citation
  • 122.

    Schuchter LM, Wingard JR, Piantadosi S. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989;74:14241427.

  • 123.

    Chanan-Khan A, Sonneveld P, Schuster MW. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:47844790.

    • Search Google Scholar
    • Export Citation
  • 124.

    Reece DE, Rodriguez GP, Chen C. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008;26:47774783.

    • Search Google Scholar
    • Export Citation
  • 125.

    Tong Y, Qian J, Li Y. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol 2007;82:403404.

  • 126.

    Varettoni M, Vassallo C, Borroni G. Late onset of bortezomib-associated cutaneous reaction following herpes zoster. Ann Hematol 2007;86:301302.

    • Search Google Scholar
    • Export Citation
  • 127.

    Amgen Inc. Prescribing information: Kyprolis (carfilzomib) for intravenous injection. 2016. Available at: http://pi.amgen.com/united_states/kyprolis/kyprolis_pi.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 128.

    Pour L, Adam Z, Buresova L. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 2009;9:151153.

    • Search Google Scholar
    • Export Citation
  • 129.

    Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009;115:229232.

    • Search Google Scholar
    • Export Citation
  • 130.

    George B, Pati N, Gilroy N. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010;12:322329.

    • Search Google Scholar
    • Export Citation
  • 131.

    Beck JC, Wagner JE, DeFor TE. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010;16:215222.

    • Search Google Scholar
    • Export Citation
  • 132.

    Milano F, Pergam SA, Xie H. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 2011;118:56895696.

    • Search Google Scholar
    • Export Citation
  • 133.

    Montesinos P, Sanz J, Cantero S. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2009;15:730740.

    • Search Google Scholar
    • Export Citation
  • 134.

    Meyers JD, Reed EC, Shepp DH. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988;318:7075.

    • Search Google Scholar
    • Export Citation
  • 135.

    Prentice HG, Gluckman E, Powles RL. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994;343:749753.

    • Search Google Scholar
    • Export Citation
  • 136.

    Ljungman P, de La Camara R, Milpied N. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002;99:30503056.

    • Search Google Scholar
    • Export Citation
  • 137.

    Reusser P, Einsele H, Lee J. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99:11591164.

    • Search Google Scholar
    • Export Citation
  • 138.

    Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992;166:473479.

    • Search Google Scholar
    • Export Citation
  • 139.

    Bacigalupo A, Tedone E, Van Lint MT. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994;13:783788.

    • Search Google Scholar
    • Export Citation
  • 140.

    Bregante S, Bertilson S, Tedone E. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant 2000;26:2329.

    • Search Google Scholar
    • Export Citation
  • 141.

    Einsele H, Reusser P, Bornhauser M. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006;107:30023008.

    • Search Google Scholar
    • Export Citation
  • 142.

    Winston DJ, Baden LR, Gabriel DA. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant 2006;12:635640.

    • Search Google Scholar
    • Export Citation
  • 143.

    Ayala E, Greene J, Sandin R. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37:851856.

    • Search Google Scholar
    • Export Citation
  • 144.

    Busca A, de Fabritiis P, Ghisetti V. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 2007;9:102107.

    • Search Google Scholar
    • Export Citation
  • 145.

    van der Heiden PL, Kalpoe JS, Barge RM. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006;37:693698.

    • Search Google Scholar
    • Export Citation
  • 146.

    Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One 2009;4:e5512.

    • Search Google Scholar
    • Export Citation
  • 147.

    Kalil AC, Mindru C, Botha JF. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl 2012;18:14401447.

    • Search Google Scholar
    • Export Citation
  • 148.

    Genentech, Inc. Prescribing information. Valcyte (valganciclovir hydrochloride) tablets, oral solution. 2015. Available at: http://www.gene.com/download/pdf/valcyte_prescribing.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 149.

    Bosi A, Bartolozzi B, Vannucchi AM. Polymerase chain reaction-based “pre-emptive” therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study. Haematologica 2002;87:446447.

    • Search Google Scholar
    • Export Citation
  • 150.

    Chakrabarti S, Collingham KE, Osman H. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant 2001;28:879881.

    • Search Google Scholar
    • Export Citation
  • 151.

    Ljungman P, Deliliers GL, Platzbecker U. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood 2001;97:388392.

    • Search Google Scholar
    • Export Citation
  • 152.

    Platzbecker U, Bandt D, Thiede C. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 2001;71:880885.

    • Search Google Scholar
    • Export Citation
  • 153.

    Nguyen Q, Champlin R, Giralt S. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999;28:618623.

    • Search Google Scholar
    • Export Citation
  • 154.

    Boeckh M, Leisenring W, Riddell SR. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407414.

    • Search Google Scholar
    • Export Citation
  • 155.

    Hakki M, Riddell SR, Storek J. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003;102:30603067.

    • Search Google Scholar
    • Export Citation
  • 156.

    Laurenti L, Piccioni P, Cattani P. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004;89:12481252.

    • Search Google Scholar
    • Export Citation
  • 157.

    Moreton P, Kennedy B, Lucas G. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:29712979.

    • Search Google Scholar
    • Export Citation
  • 158.

    Nguyen DD, Cao TM, Dugan K. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002;3:105110.

    • Search Google Scholar
    • Export Citation
  • 159.

    O'Brien S, Ravandi F, Riehl T. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008;111:18161819.

    • Search Google Scholar
    • Export Citation
  • 160.

    Montillo M, Schinkoethe T, Elter T. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest 2005;23:488496.

    • Search Google Scholar
    • Export Citation
  • 161.

    Moretti S, Zikos P, Van Lint MT. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 1998;22:175180.

    • Search Google Scholar
    • Export Citation
  • 162.

    US Food and Drug Administration. Prescribing information. Foscavir (foscarnet) for injection. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020068s020lbl.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 163.

    Gilead Sciences, Inc. Prescribing information. Vistide (cidofovir) injection. 2010. Available at: http://www.gilead.com/~/media/files/pdfs/medicines/other/vistide/vistide.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 164.

    O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006;7:125130.

    • Search Google Scholar
    • Export Citation
  • 165.

    Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009;113:31473153.

    • Search Google Scholar
    • Export Citation
  • 166.

    Brechot C, Degos F, Lugassy C. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985;312:270276.

    • Search Google Scholar
    • Export Citation
  • 167.

    Dhedin N, Douvin C, Kuentz M. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998;66:616619.

    • Search Google Scholar
    • Export Citation
  • 168.

    Borentain P, Colson P, Coso D. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 2010;17:807815.

    • Search Google Scholar
    • Export Citation
  • 169.

    Evens AM, Jovanovic BD, Su YC. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22:11701180.

    • Search Google Scholar
    • Export Citation
  • 170.

    Fukushima N, Mizuta T, Tanaka M. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009;20:20132017.

    • Search Google Scholar
    • Export Citation
  • 171.

    Ji D, Cao J, Hong X. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. Eur J Haematol 2010;85:243250.

    • Search Google Scholar
    • Export Citation
  • 172.

    Koo YX, Tan DS, Tan IB. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010;116:115121.

    • Search Google Scholar
    • Export Citation
  • 173.

    Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699712.

    • Search Google Scholar
    • Export Citation
  • 174.

    Lau GKK, He ML, Fong DY. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702709.

    • Search Google Scholar
    • Export Citation
  • 175.

    Matsue K, Kimura S, Takanashi Y. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010;116:47694776.

    • Search Google Scholar
    • Export Citation
  • 176.

    Yeo W, Chan PK, Zhong S. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299307.

    • Search Google Scholar
    • Export Citation
  • 177.

    Yeo W, Chan TC, Leung NW. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605611.

    • Search Google Scholar
    • Export Citation
  • 178.

    Liang RH, Lok AS, Lai CL. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990;8:261270.

  • 179.

    Dai MS, Lu JJ, Chen YC. Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 2001;92:29272932.

  • 180.

    Steinberg JL, Yeo W, Zhong S. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 2000;60:249255.

    • Search Google Scholar
    • Export Citation
  • 181.

    Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975;2:528530.

    • Search Google Scholar
    • Export Citation
  • 182.

    Pinto PC, Hu E, Bernstein-Singer M. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990;65:878884.

    • Search Google Scholar
    • Export Citation
  • 183.

    Yeo W, Chan PK, Hui P. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003;70:553561.

    • Search Google Scholar
    • Export Citation
  • 184.

    Yeo W, Hui EP, Chan AT. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005;28:379384.

    • Search Google Scholar
    • Export Citation
  • 185.

    Vigano M, Vener C, Lampertico P. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011;46:125131.

    • Search Google Scholar
    • Export Citation
  • 186.

    Hammond SP, Borchelt AM, Ukomadu C. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:10491059.

    • Search Google Scholar
    • Export Citation
  • 187.

    Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:5862.

    • Search Google Scholar
    • Export Citation
  • 188.

    Yeo W, Chan PKS, Ho WM. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927934.

    • Search Google Scholar
    • Export Citation
  • 189.

    Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:9981005.

    • Search Google Scholar
    • Export Citation
  • 190.

    Giaccone L, Festuccia M, Marengo A. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:809817.

    • Search Google Scholar
    • Export Citation
  • 191.

    Gish RG. Hepatitis B treatment: Current best practices, avoiding resistance. Cleve Clin J Med 2009;76(Suppl 3):S1419.

  • 192.

    Cortelezzi A, Vigano M, Zilioli VR. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 2006;35:467469.

    • Search Google Scholar
    • Export Citation
  • 193.

    Peters MG, Hann HW, Martin P. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91101.

    • Search Google Scholar
    • Export Citation
  • 194.

    Marcellin P, Heathcote EJ, Buti M. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:24422455.

    • Search Google Scholar
    • Export Citation
  • 195.

    Kitrinos KM, Corsa A, Liu Y. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014;59:434442.

    • Search Google Scholar
    • Export Citation
  • 196.

    Marcellin P, Gane E, Buti M. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468475.

    • Search Google Scholar
    • Export Citation
  • 197.

    Leung N, Peng CY, Hann HW. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:7279.

    • Search Google Scholar
    • Export Citation
  • 198.

    Chan HL, Heathcote EJ, Marcellin P. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745754.

    • Search Google Scholar
    • Export Citation
  • 199.

    Watanabe M, Shibuya A, Takada J. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med 2010;21:333337.

    • Search Google Scholar
    • Export Citation
  • 200.

    Liu WP, Zheng W, Song YQ. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma. World J Gastroenterol 2014;20:51655170.

    • Search Google Scholar
    • Export Citation
  • 201.

    Tenney DJ, Rose RE, Baldick CJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:15031514.

    • Search Google Scholar
    • Export Citation
  • 202.

    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:17431751.

    • Search Google Scholar
    • Export Citation
  • 203.

    Heathcote EJ, Marcellin P, Buti M. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132143.

    • Search Google Scholar
    • Export Citation
  • 204.

    European Association For The Study Of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167185.

    • Search Google Scholar
    • Export Citation
  • 205.

    Wang Y, Thongsawat S, Gane EJ. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat 2013;20:e3746.

    • Search Google Scholar
    • Export Citation
  • 206.

    Ha NB, Ha NB, Garcia RT. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727734.

  • 207.

    Izzedine H, Hulot JS, Launay-Vacher V. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66:11531158.

    • Search Google Scholar
    • Export Citation
  • 208.

    Nelson MR, Katlama C, Montaner JS. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:12731281.

    • Search Google Scholar
    • Export Citation
  • 209.

    Liaw YF, Gane E, Leung N. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486495.

    • Search Google Scholar
    • Export Citation
  • 210.

    Goncalves J, Laeufle R, Avila C. Increased risk with combination of telbivudine and pegylated-interferon Alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from the novartis global database [abstract]. J Hepatol 2009;50:Abstract 907.

    • Search Google Scholar
    • Export Citation
  • 211.

    Artz AS, Somerfield MR, Feld JJ. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010;28:31993202.

    • Search Google Scholar
    • Export Citation
  • 212.

    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661662.

  • 213.

    McQuillan GM, Townsend TR, Johannes CB. Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population. Am J Epidemiol 1987;126:484491.

    • Search Google Scholar
    • Export Citation
  • 214.

    IOM. Hepatitis and liver cancer: A national strategy for prevention and control of hepatitis B and C: National Academies Press; 2010. Available at: http://www.cdc.gov/hepatitis/pdfs/iom-hepatitisandlivercancerreport.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 215.

    Hatzakis A, Wait S, Bruix J. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011;18(Suppl 1):116.

    • Search Google Scholar
    • Export Citation
  • 216.

    Weinbaum CM, Williams I, Mast EE. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:120.

    • Search Google Scholar
    • Export Citation
  • 217.

    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:13351374.

  • 218.

    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507539.

  • 219.

    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas v.3.2016. Available at: www.nccn.org. Accessed May 12, 2016.

    • Search Google Scholar
    • Export Citation
  • 220.

    Lee MH, Yang HI, Lu SN. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469477.

    • Search Google Scholar
    • Export Citation
  • 221.

    Yazici O, Sendur MA, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol 2014;20:67166724.

    • Search Google Scholar
    • Export Citation
  • 222.

    Borchardt RA, Torres HA. Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol 2014;20:27712776.

  • 223.

    AASLD/IDSA: recommendations for testing, managing, and treating hepatitis C. Available at: www.hcvguidelines.org. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 224.

    Prevention CfDCa. HIV Surveillance Report. Vol. 25; 2013. Available at: http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed June 22, 2016.

    • Search Google Scholar
    • Export Citation
  • 225.

    Chiao EY, Dezube BJ, Krown SE. Time for oncologists to opt in for routine opt-out HIV testing? JAMA 2010;304:334339.

  • 226.

    Silverberg MJ, Chao C, Leyden WA. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011;20:25512559.

    • Search Google Scholar
    • Export Citation
  • 227.

    Shiels MS, Pfeiffer RM, Gail MH. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103:753762.

  • 228.

    Biggar RJ, Engels EA, Ly S. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005;39:293299.

  • 229.

    Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol 2005;2:406415; quiz 423.

    • Search Google Scholar
    • Export Citation
  • 230.

    Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011;12:905912.

  • 231.

    Hwang JP, Granwehr BP, Torres HA. HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center. J Oncol Pract 2015;11:384390.

    • Search Google Scholar
    • Export Citation
  • 232.

    Branson BM, Handsfield HH, Lampe MA. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:117.

    • Search Google Scholar
    • Export Citation
  • 233.

    Gross AE, Bryson ML. Oral ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review. Ann Pharmacother 2015;49:11251135.

    • Search Google Scholar
    • Export Citation
  • 234.

    Beaird OE, Freifeld A, Ison MG. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis 2016;18:210215.

    • Search Google Scholar
    • Export Citation
  • 235.

    Hoellein A, Hecker J, Hoffmann D. Serious outbreak of human metapneumovirus in patients with hematologic malignancies. Leuk Lymphoma 2016;57:623627.

    • Search Google Scholar
    • Export Citation
  • 236.

    Godet C, Le Goff J, Beby-Defaux A. Human metapneumovirus pneumonia in patients with hematological malignancies. J Clin Virol 2014;61:593596.

    • Search Google Scholar
    • Export Citation
  • 237.

    Shah DP, Shah PK, Azzi JM, Chemaly RF. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review. Cancer Lett 2016;370:358364.

    • Search Google Scholar
    • Export Citation
  • 238.

    Anak S, Atay D, Unuvar A. Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT. Pediatr Pulmonol 2010;45:307311.

    • Search Google Scholar
    • Export Citation
  • 239.

    Choi JH, Choi EH, Kang HJ. Respiratory viral infections after hematopoietic stem cell transplantation in children. J Korean Med Sci 2013;28:3641.

    • Search Google Scholar
    • Export Citation
  • 240.

    Khanna N, Widmer AF, Decker M. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008;46:402412.

    • Search Google Scholar
    • Export Citation
  • 241.

    Asner S, Stephens D, Pedulla P. Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children. Pediatr Infect Dis J 2013;32:10731076.

    • Search Google Scholar
    • Export Citation
  • 242.

    Lo MS, Lee GM, Gunawardane N. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant 2013;17:133143.

    • Search Google Scholar
    • Export Citation
  • 243.

    Whimbey E, Champlin RE, Englund JA. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995;16:393399.

    • Search Google Scholar
    • Export Citation
  • 244.

    Marcelin JR, Wilson JW, Razonable RR. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 2014;16:242250.

    • Search Google Scholar
    • Export Citation
  • 245.

    Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza. MMWR Morb Mortality Wkly Rep 2011;60:126.

    • Search Google Scholar
    • Export Citation
  • 246.

    Fiore AE, Fry A, Shay D. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:124.

    • Search Google Scholar
    • Export Citation
  • 247.

    Mandell LA, Wunderink RG, Anzueto A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):2772.

    • Search Google Scholar
    • Export Citation
  • 248.

    US Food and Drug Administration. Prescribing information. Tamiflu (oseltamivir phosphate). 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 249.

    US Food and Drug Administration. Prescribing information. Relenza (zanamivir) inhalation powder for oral inhalation. 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021036s027lbl.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 250.

    US Food and Drug Administration. Influenza (flu) antiviral drugs and related information. Rockville, MD: 2013. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm100228.htm. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 251.

    Ison MG, Hui DS, Clezy K. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 2013;18:651661.

    • Search Google Scholar
    • Export Citation
  • 252.

    US Food and Drug Administration. Prescribing information. Rapivab (peramivir) for intravenous injection. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 253.

    Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997;102:2730.

    • Search Google Scholar
    • Export Citation
  • 254.

    Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 2001;7(Suppl):5S7S.

    • Search Google Scholar
    • Export Citation
  • 255.

    Whimbey E, Champlin RE, Couch RB. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996;22:778782.

    • Search Google Scholar
    • Export Citation
  • 256.

    Feldman S, Webster RG, Sugg M. Influenza in children and young adults with cancer: 20 cases. Cancer 1977;39:350353.

  • 257.

    Kempe A, Hall CB, MacDonald NE. Influenza in children with cancer. J Pediatr 1989;115:3339.

  • 258.

    Elting LS, Whimbey E, Lo W. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995;3:198202.

    • Search Google Scholar
    • Export Citation
  • 259.

    Fiore AE, Uyeki TM, Broder K. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:162.

    • Search Google Scholar
    • Export Citation
  • 260.

    Harper SA, Fukuda K, Cox NJ, Bridges CB. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52:18.

    • Search Google Scholar
    • Export Citation
  • 261.

    Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases, 13th edition. Washington DC: Centers for Disease Control and Prevention, Public Health Foundation; 2015.

    • Search Google Scholar
    • Export Citation
  • 262.

    Recommended adult immunization schedule: United States, 2012. Ann Intern Med 2012;156:211217.

  • 263.

    Engelhard D, Akova M, Boeckh MJ. Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:467470.

    • Search Google Scholar
    • Export Citation
  • 264.

    Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:148.

    • Search Google Scholar
    • Export Citation
  • 265.

    Davies JM, Lewis MP, Wimperis J. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol 2011;155:308317.

    • Search Google Scholar
    • Export Citation
  • 266.

    Rubin LG, Schaffner W. Clinical practice. Care of the asplenic patient. N Engl J Med 2014;371:349356.

  • 267.

    Recommended adult immunization schedule—United States, 2010. Advisory Committee on Immunization Practices and the Centers for Disease Control and Prevention; 2010. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5901a5.htm. Accessed April 29, 2016.

    • Search Google Scholar
    • Export Citation
  • 268.

    Zugmaier G, Topp MS, Alekar S. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 2014;4:244.

    • Search Google Scholar
    • Export Citation
  • 269.

    Bluml S, McKeever K, Ettinger R. B-cell targeted therapeutics in clinical development. Arthritis Res Ther 2013;15(Suppl 1):S4.

  • 270.

    Diwakar L, Gorrie S, Richter A. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 2010;63:275277.

  • 271.

    Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013;13:106111.

    • Search Google Scholar
    • Export Citation
  • 272.

    Walker AR, Kleiner A, Rich L. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest 2008;26:431433.

  • 273.

    Irie E, Shirota Y, Suzuki C. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 2010;91:501508.

    • Search Google Scholar
    • Export Citation
  • 274.

    Kasamon YL, Jones RJ, Brodsky RA. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol 2010;21:12031210.

    • Search Google Scholar
    • Export Citation
  • 275.

    Nishio M, Fujimoto K, Yamamoto S. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol 2007;137:349354.

    • Search Google Scholar
    • Export Citation
  • 276.

    Ortbals DW, Liebhaber H, Presant CA. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977;87:552557.

  • 277.

    Sommer AL, Wachel BK, Smith JA. Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy. J Oncol Pharm Pract 2006;12:143154.

    • Search Google Scholar
    • Export Citation